Boston, Massachusetts Clinical Trials

A listing of Boston, Massachusetts clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 104 clinical trials
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

absolute neutrophil count
ibrutinib
myd88 gene mutation
venetoclax
measurable disease
Massachusetts General Hospital
 (0.5 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
MINDFUL-PC for Portuguese Speakers Pilot Study 2020

The study evaluates the effects of the Mindfulness Training for Primary Care (MTPC) Portuguese-adapted version on heart rate variability during a demanding cognitive task. The study also evaluates the effects on mental health, quality of life, self-regulation and behavior outcomes. The study will also complete the MTPC cultural adaptation process …

chronic disease
insomnia
anxiety
depression
stress disorders
Cambridge Health Alliance
 (2.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
CIML NK Cell in Head & Neck Cancer

This research study is evaluating the safety and efficacy of a combination drug and biologic therapy in patients with advanced head and neck cancer. This research study involves the following drugs and biologics: CIML NK donor cells IL-15 superagonist Ipilimumab

prednisone
oropharyngeal
ipilimumab
biological therapy
biologics
Dana Farber Cancer Institute
 (1.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Lorlatinib Combinations in Lung Cancer

This research study is evaluating Lorlatinib in combination with Crizotinib or Binimetinib as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. This research study involves three study drugs. Lorlatinib Binimetinib Crizotinib

core needle biopsy
tyrosine
met amplification
cns lesion
measurable disease
Massachusetts General Hospital Cancer Center
 (0.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

neurofibroma
nf2 gene
measurable disease
schwartz
neutrophil count
Children's Hospital Boston (Site 725)
 (1.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +16 other locations
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancers type are NSCLC and melanoma that are progressing …

monoclonal antibodies
systemic therapy
ipilimumab
endometrioid adenocarcinoma of the endometrium
measurable disease
Massachusetts General Hospital Cancer Center
 (0.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +8 other locations
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

her2- breast cancer
palbociclib
epidermal growth factor
epidermal growth factor receptor
breast cancer
Massachusetts General Hospital
 (0.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +6 other locations
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

kras g12c mutation
metastatic malignant solid tumor
kras
ki-ras
solid tumour
Dana Farber Cancer Institute
 (1.8 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +7 other locations
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Ipatasertib Atezolizumab

triple negative breast neoplasms
treatment regimen
breast cancer
serum bilirubin level
lymphadenectomy
Dana-Farber Cancer Institute
 (1.8 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Randomized Controlled Trial of AppS to Home Monitor Your Asthma

The objective of this study is to design, implement, and evaluate the impact of an adapted health information technology(IT)-enabled practice model for asthma symptom monitoring using patient-reported outcomes (PROs) in a primary care setting. Adults over 18 years of age with asthma will be recruited at four primary care clinics …

Brigham & Women's Hospital
 (1.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location